Norepinephrine-dopamine reuptake inhibitor

Norepinephrine-dopamine reuptake inhibitor (NDRI) is a class of drugs used primarily in the treatment of depression and attention deficit hyperactivity disorder (ADHD). The term refers to any medication that inhibits the reuptake of norepinephrine and dopamine by blocking the action of the norepinephrine-dopamine reuptake pump.

Pronunciation

Norepinephrine-dopamine reuptake inhibitor: /ˌnɔːrɛpɪˈnɛfrɪn doʊˈpæmɪn riːˈʌptək ɪnˈhɪbɪtər/

Etymology

The term "Norepinephrine-dopamine reuptake inhibitor" is derived from the names of the two neurotransmitters it affects (norepinephrine and dopamine) and the process it inhibits (reuptake).

Pharmacology

NDRIs work by blocking the reuptake of norepinephrine and dopamine, two neurotransmitters in the brain. This increases the amount of these neurotransmitters available to bind to receptors, which can help to alleviate symptoms of depression and ADHD.

Examples

Some examples of NDRIs include bupropion (Wellbutrin), methylphenidate (Ritalin), and atomoxetine (Strattera).

Side Effects

Common side effects of NDRIs can include insomnia, nausea, and dry mouth. More serious side effects can include seizures and psychosis.

See Also

• Selective serotonin reuptake inhibitor
• Serotonin-norepinephrine reuptake inhibitor
• Dopamine reuptake inhibitor

This WikiMD.org article is a stub. You can help make it a full article.